# InMed Pharmaceuticals Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/InMed Pharmaceuticals Inc.). ## Overview InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical drug development company focused on proprietary small-molecule candidates for diseases with high unmet medical need. Through its BayMedica subsidiary, it also manufactures and sells bulk rare, non-intoxicating cannabinoids as ingredients for health and wellness applications. ## Products & services • INM-089 ocular neuroprotection program for dry AMD • INM-755 (cannabinol) cream for EB-related itch and skin conditions • INM-901 Alzheimer’s disease drug candidate • Bulk rare cannabinoid ingredients via BayMedica • Chemical synthesis, biosynthesis and IntegraSyn manufacturing - **Pharmaceutical drug candidates** (0%) — Early-stage proprietary compounds being developed for ocular, dermatology and neurodegenerative indications. - **Cannabinoid ingredients** (100%) — Bulk rare cannabinoids manufactured and sold to B2B customers for health and wellness uses. - **Contracted R&D and development** (0%) — Research, formulation, CMC and clinical development work supporting pipeline advancement. - **Manufacturing services and processes** (0%) — Proprietary and conventional manufacturing approaches used to produce high-purity cannabinoid products. - INM-089 small-molecule ocular program for dry AMD neuroprotection - INM-755 cannabinol cream for epidermolysis bullosa and itch - INM-901 oral candidate for Alzheimer’s disease - Bulk rare, non-intoxicating cannabinoids sold as raw materials - Chemical synthesis, biosynthesis and IntegraSyn manufacturing ## Customers InMed’s commercial customers are B2B buyers of rare cannabinoid raw materials, likely including ingredient formulators and health-and-wellness product companies. On the pharmaceutical side, the company’s end customers are future patients, but near-term economic value depends on regulators, clinical investigators, and potential licensing or partnership counterparties. The business is therefore split between ingredient sales today and long-duration drug development programs that may monetize through approval or partnering. - **B2B cannabinoid ingredient buyers** (primary) — Buy bulk rare, non-intoxicating cannabinoids for use as raw materials in health and wellness products. - **Pharmaceutical licensing partners** (secondary) — May license or co-develop INM-755 and other pipeline assets to reduce development risk and fund advancement. - **Clinical and research ecosystem** (secondary) — CROs, CDMOs, investigators and consultants supporting preclinical and clinical development work. - **Future prescription patients** (emerging) — Patients with dry AMD, epidermolysis bullosa, itch-related skin conditions and Alzheimer’s disease. - Health and wellness ingredient buyers purchasing bulk cannabinoids - Formulators needing bioidentical rare cannabinoids as raw materials - Potential pharma partners evaluating INM-755 or INM-901 - Clinical and regulatory stakeholders enabling drug development - Future patients in dry AMD, EB, itch and Alzheimer’s indications ## Geography InMed is headquartered in Vancouver, British Columbia, and is listed on Nasdaq in the United States. Its business is cross-border: development, manufacturing and commercial activities are influenced by U.S. and Canadian regulation, while trade policy and import/export conditions can affect BayMedica’s ingredient business. - Headquartered in Vancouver, British Columbia, Canada - Listed on Nasdaq Capital Market in the United States - Commercial cannabinoid sales are exposed to cross-border trade rules - U.S. and Canadian healthcare regulation shapes drug development - Manufacturing approach supports flexible sourcing and production ## Strategy InMed is prioritizing advancement of its proprietary pipeline while keeping BayMedica’s cannabinoid ingredient business as the current revenue base. Management is also pursuing strategic partnership opportunities for INM-755 and scaling CMC work for INM-901 to support future clinical entry and potential licensing value. - **Advance pipeline assets toward clinical and regulatory milestones** (medium-term) — Clinical progress is the main path to value creation for a company with no approved products. - **Monetize BayMedica’s cannabinoid ingredient business** (short-term) — Commercial sales provide the only recurring revenue source while the pharma pipeline remains pre-revenue. - **Pursue strategic partnerships** (medium-term) — Partnering can reduce capital intensity and improve the odds of advancing assets like INM-755. - Advance INM-089, INM-755 and INM-901 toward clinical milestones - Use BayMedica to generate commercial revenue from rare cannabinoids - Pursue partnerships for INM-755 to share development risk - Scale manufacturing and CMC capabilities for future drug programs - Maintain flexibility across synthesis, biosynthesis and IntegraSyn ## Risks InMed is highly exposed to clinical, regulatory and financing risk because its drug candidates are early-stage and unapproved. The BayMedica business adds commercial and policy risk, including possible inventory write-offs, trade disruption and regulatory changes affecting cannabinoid ingredients. - **Clinical development failure** [high] — Product candidates are early stage and may not demonstrate safety or efficacy in trials. - **Regulatory approval delay or denial** [high] — Drug candidates require lengthy and unpredictable FDA/Health Canada review processes. - **Cannabinoid market and policy change** [high] — BayMedica’s commercial inventory and sales depend on the legal treatment of non-intoxicating cannabinoids. - **Nasdaq minimum bid price or listing compliance** [medium] — Delisting risk can reduce liquidity and access to capital for a small-cap development company. - **Financing and going-concern pressure** [high] — The company has recurring operating losses and relies on external capital to fund operations. - Early-stage pipeline has a high probability of clinical or regulatory failure - No approved products means future revenue depends on uncertain development outcomes - Nasdaq listing compliance risk could pressure liquidity and market access - Cannabinoid regulation or trade policy could force inventory write-offs - Limited cash and ongoing losses increase financing dependence ## Accounting Revenue is recognized at a point in time when BayMedica’s products transfer control to the customer, so shipment timing and inventory sell-through can move quarterly results. Investors should also watch going-concern judgments, share-based compensation, inventory write-downs, warrant valuations and R&D accrual estimates, all of which can materially affect reported losses and balance-sheet values. - **Revenue recognition timing** — BayMedica sales and gross margin - **Going-concern assessment** — Liquidity disclosure and investor perception - **Inventory valuation** — Cost of sales and asset values - **Share-based compensation and warrant valuation** — Reported net loss and equity - **R&D accrual estimates** — Research and development expense - Point-in-time revenue recognition for bulk cannabinoid sales - Going-concern assessment reflects liquidity and funding needs - Inventory write-down risk if cannabinoid products cannot be sold - Share-based compensation and warrant valuation affect expenses - R&D accruals and fair value estimates can shift quarterly losses --- *Last updated: 2026-04-28T20:17:07.586268+00:00*